2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-151929
    JNK3 inhibitor-4 2409109-65-3 99.37%
    JNK3 inhibitor-4 is a potent inhibitor of JNK3 (IC50=1.0 nM) based on 2-aryl-1-pyrimidinyl-1H-imidazole-5-yl acetonitrile. JNK3 inhibitor-4 shows excellent selectivity over other protein kinases including isoforms JNK1 (IC50=143.9 nM) and JNK2 (IC50=298.2 nM). JNK3 inhibitor-4 has neuroprotective effect and predicated blood-brain barrier permeability.
    JNK3 inhibitor-4
  • HY-152949
    Myosin V-IN-1 1259177-59-7
    Myosin V-IN-1 (compound 8) is a potent and selective Myosin V inhibitor, with a Ki of 6 μM. Myosin V-IN-1 shows acute inhibition of myosin V. Myosin V-IN-1 slows the actin-activated myosin V ATPase by specifically inhibiting ADP release from the actomyosin complex.
    Myosin V-IN-1
  • HY-153166
    PT-65 2721998-87-2 98.4%
    PT-65 is a potent and selective GSK3 PROTAC degrader with the highest degradation capacity of GSK3α (DC50= 28.3 nM) and GSK3β (DC50= 34.2 nM) in SH-SY5Y cells. PT-65 can be used in Alzheimer's disease research.(Pink: GSK3 inhibitor (HY-15761); Black: linker; Blue: CRBN Ligand (HY-10984))
    PT-65
  • HY-153530
    LI-2242 2762762-17-2 98.95%
    LI-2242 is an inositol hexakisphosphate kinase (IP6K) inhibitor. LI-2242 has inhibition effect for IP6K1, IP6K2, IP6K3 and IPMK with IC50 values of 31 nM, 42 nM, 8.7 nM and 1944 nM, respectively. LI-2242 can be used for thew research of type II diabetes, obesity, metabolic complications, venous thrombosis, and psychiatric disorders.
    LI-2242
  • HY-153609
    AS-Patisiran sodium
    AS-Patisiran sodium is an antisense strand of Patisiran. Patisiran is a double-stranded small interfering RNA that targets a sequence within the transthyretin (TTR) messenger RNA. Patisiran specifically inhibits hepatic synthesis of mutant and wild-type TTR. Patisiran can be used for the research of hereditary TTR amyloidosis.
    AS-Patisiran sodium
  • HY-155111
    nSMase2-IN-1 2968322-24-7 98.24%
    nSMase2-IN-1 is an orally active Neutral sphingomyelinase 2 (nSMase2) inhibitor with an IC50 value of 0.13 ± 0.06 μM. nSMase2-IN-1 is metabolically stable in liver microsomes and orally available with a favorable brain-to-plasma ratio. nSMase2-IN-1 can be used for nervous system disease research.
    nSMase2-IN-1
  • HY-155482
    NA-184 2688119-39-1 99.66%
    NA-184 is a selective and brain-penetrant calpain-2 inhibitor with an IC50 of 134 nM for mouse calpain-2. NA-184 has weak inhibitory activity on calpain-1 (IC50 of 2826 nM). NA-184 does not exhibit significant inhibition on a variety of other cysteine-, serine- or metallo-proteases. NA-184 shows significant neuroprotection and can be used for the study of traumatic brain injury (TBI).
    NA-184
  • HY-155612
    M826 321437-16-5 99.75%
    M826 is a potent, selective and reversible non-peptide caspase-3 inhibitor with an IC50 value of 0.005 μM for enzymatic activity against caspase-3. M826 displays potent anti-apoptotic activity in animal models in vitro and in vivo. M826 can be used for nervous system diseases research.
    M826
  • HY-156103
    mHTT-IN-2 2743336-70-9 99.35%
    mHTT-IN-2 (compound 27) is a potent inhibitor (EC50=0.066 μM) of mutant huntingtin (mHTT). mHTT-IN-2 reduces canonical splicing of HTT RNA exons [49-50] and is a splicing regulator of the huntingtin (HTT) gene. mHTT-IN-2 exhibits inhibitory activity in vitro and in vivo in human HD stem cells and mouse BACHD models. mHTT-IN-2 may be used in the study of branaplam-related peripheral neuropathy.
    mHTT-IN-2
  • HY-160116
    α-Synuclein aggregate binder 1 1565797-17-2 98.11%
    α-Synuclein aggregate binder 1 (Compound C05-05) is a specific binder for α-synuclein aggregates and can inhibit α-synuclein aggregation. α-Synuclein aggregate binder 1 can be used as a fluorescent probe (excitation wavelength 900 nm, detection wavelength 500-550 nm) for optical imaging, and can also inhibit α-synuclein fibril formation by blocking the aggregation process. α-Synuclein aggregate binder 1 can be used for positron emission tomography (PET) imaging after being labeled with 18F. α-Synuclein aggregate binder 1 can be used for visual diagnosis of brain lesions and mechanism research of neurodegenerative diseases such as Parkinson's disease and Lewy body dementia.
    α-Synuclein aggregate binder 1
  • HY-162549
    CPK20 2397708-22-2 99.67%
    CPK20 is a potent and highly selective KCNT1 channel blocker, and CPK20 can be used in the study of epilepsy.
    CPK20
  • HY-162566
    REM127 1417823-67-6 ≥98.0%
    REM127 is a small molecule compound capable of modulating calcium homeostasis in cells and possesses neuroprotective effects. REM127 can restore the calcium homeostasis imbalance in cellular models caused by pathological accumulation of tau protein. REM127 can efficiently cross the blood-brain barrier, and it has the potential to rescue synaptic and cognitive deficits in Alzheimer's disease animal models, as well as to slow down the progression of amyloid-beta and tau protein pathologies. REM127 can be used for research in neurodegenerative diseases.
    REM127
  • HY-163095
    RH1115 3080978-62-4 98.92%
    RH1115 (compound 2c) is a modulator of the autophagy-lysosome. RH1115 induces changes to LAMP1 vesicle properties and alters lysosome positioning.
    RH1115
  • HY-163171
    ARN11391 1214569-31-9 99.40%
    ARN 11391 is a selective enhancer of inositol triphosphate receptor type 1 (ITPR1). ARN 11391 can be used in the study of spinocerebellar ataxia.
    ARN11391
  • HY-163200
    Cu(I) chelator 1 ≥98.0%
    Cu(I) chelator 1 (Compound LH2) is a chelator which targets the Cu(I) redox state. Cu(I) chelator 1 prevents ROS production.
    Cu(I) chelator 1
  • HY-163763
    T-10418 1608784-68-4 99.78%
    T-10418 is a potent and highly selective G2A/GPR132 agonist. T-10418 has an EC50 of 0.82 μM for human G2A activation. T-10418 has good water solubility, metabolic stability, and pharmacokinetic properties. T-10418 can be used for the research of various diseases such as neuropathic pain, acute myeloid leukemia, and inflammation.
    T-10418
  • HY-163987
    SIRT3 activator 2 3061491-60-6 98.94%
    SIRT3 activator 2 (compound 2a) is a SIRT3 activator. SIRT3 activator 2 improved the thermal stability of SIRT3 in SH-SY5Y cells, indicating that it can directly bind to SIRT3, has SIRT3 dependency in SH-SY5Y to clear α-Syn. SIRT3 activator 2 improves motor function in Parkinson mice, preventing Parkinson (DA) neuron loss in the substantia nigra in a dose-dependent manner.
    SIRT3 activator 2
  • HY-164907
    GSK-3β inhibitor 22 1005199-84-7 98.57%
    GSK-3β inhibitor 22 (compound 20o) is a GSK-3β inhibitor with an IC50 of 3.1 nM. GSK-3β inhibitor 22 has the potential of the study of Alzheimer's disease.
    GSK-3β inhibitor 22
  • HY-16688A
    RU 24969 succinate 107008-28-6 99.58%
    RU 24969 succinate is a 5-HT receptor agonist with Ki values of 0.38 and 2.5 nM for 5-HT1B and 5-HT1A, respectively. RU 24969 decreases fluid consumption and increases forward locomotion. RU 24969 succinate can be used for the research of neurological disease.
    RU 24969 succinate
  • HY-16713A
    (S)-(-)-5-Fluorowillardiine hydrochloride 1321546-70-6 99.03%
    (S)-(-)-5-Fluorowillardiine hydrochloride is a potent and specific AMPAR agonist.
    (S)-(-)-5-Fluorowillardiine hydrochloride
Cat. No. Product Name / Synonyms Application Reactivity